The present disclosure relates to a nanostructure for detecting viruses including an amphipathic polymer, and a diagnostic platform using the same, wherein the nanostructure is capable of specifically detecting viruses through silica-based nanoparticles with excellent stability and high dispersion and a biocompatible amphipathic polymer, such that it is possible to develop a diagnostic platform with high sensitivity through binding and agglomeration of the nanostructure and viruses and enable rapid and accurate diagnosis of a target virus.

The application discloses a method, kit and system for preparing an antibody pair, and the use of the kit. Wherein the method comprises using an antigen-binding fragment of an existing antibody as a capture antibody and using an anti-crystallizable fragment antibody as a labelled antibody to directly screen a target antibody which can be paired with the existing antibody from cell culture supernatant. By using the technical solution of the present application, the cell culture supernatant can be directly screened to obtain the antibody pair without requiring a large-scale preparation, purification and labelling of the antibody to be screened, thereby greatly reducing the workload.

The application discloses a method, kit and system for preparing an antibody pair, and the use of the kit. Wherein the method comprises using an antigen-binding fragment of an existing antibody as a capture antibody and using an anti-crystallizable fragment antibody as a labelled antibody to directly screen a target antibody which can be paired with the existing antibody from cell culture supernatant. By using the technical solution of the present application, the cell culture supernatant can be directly screened to obtain the antibody pair without requiring a large-scale preparation, purification and labelling of the antibody to be screened, thereby greatly reducing the workload.

An analyte capture device and related systems and methods are provided. The analyte capture device includes a glass material, an outer surface defined by the glass material, and a plurality of pores formed in the glass material along at least a portion of the outer surface. The analyte capture device is exposed to an environment containing an analyte for a period of time such that the analyte is captured within the plurality of pores of the glass material. The concentration of the analyte within the glass material is greater than a concentration of the analyte within the environment. The analyte capture device is then removed from the environment, and a property of the analyte within the analyte capture device is detected via an analyte detection system.

Embodiments of the present invention provide a lateral flow assay method and strip wherein a sample is injected into a sample pad, a preconcentration kit is coupled to the sample pad to preconcentrate analytes, and a conjugate pad or a test pad is connected to the sample pad to transfer the analytes to the conjugate pad or the test pad, whereby a biomarker present at a low concentration can be detected.

Embodiments of the present invention provide a lateral flow assay method and strip wherein a sample is injected into a sample pad, a preconcentration kit is coupled to the sample pad to preconcentrate analytes, and a conjugate pad or a test pad is connected to the sample pad to transfer the analytes to the conjugate pad or the test pad, whereby a biomarker present at a low concentration can be detected.

The present invention relates to systems that utilize a combination of immunoassay and magnetic immunoassay techniques to detect an analyte within an extended range of specified concentrations. In particular, a device is provided for detecting an analyte in a biological sample. The device includes a first electrochemical sensor positioned on a substrate. The first electrochemical sensor includes an immobilized layer of antibody configured to bind to the analyte. The device further includes a second electrochemical sensor positioned adjacent to the first electrochemical sensor on the substrate, and a magnetic material that generates a magnetic field aligned with respect to the second electrochemical sensor. The magnetic field captures magnetic beads that have an immobilized layer of antibody configured to bind to the analyte, and concentrates the magnetic beads on or near a surface of the second electrochemical sensor.

The present invention relates to systems that utilize a combination of immunoassay and magnetic immunoassay techniques to detect an analyte within an extended range of specified concentrations. In particular, a device is provided for detecting an analyte in a biological sample. The device includes a first electrochemical sensor positioned on a substrate. The first electrochemical sensor includes an immobilized layer of antibody configured to bind to the analyte. The device further includes a second electrochemical sensor positioned adjacent to the first electrochemical sensor on the substrate, and a magnetic material that generates a magnetic field aligned with respect to the second electrochemical sensor. The magnetic field captures magnetic beads that have an immobilized layer of antibody configured to bind to the analyte, and concentrates the magnetic beads on or near a surface of the second electrochemical sensor.

Provided is a composition comprising an analyte bound covalently or through a first binding pair to a polymer. In this composition, the analyte is less than about 2000 MW; the polymer further comprises more than one signal or first member of a second binding pair; and the analyte is not a member of the first binding pair or the second binding pair. Also provided is an assay for an analyte. The assay comprises: combining a sample suspected of containing the analyte with the above-described composition and a binding agent that binds to the analyte; and detecting the signal or the first member of the second binding pair that is bound to the binding agent. Additionally provided is a multisignal labeling reagent comprising a first polymer covalently bound to (a) a reactive group or a first member of a first binding pair, and (b) more than one digoxigenin molecule.

Provided herein is a newly developed immunoassay that can detect progerin with high sensitivity, but which does not detect wildtype lamin A. Applications of the newly developed immunoassay in novel methods for diagnosing, prognosing, and treating progeria are also described.